Cannabidiol
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
CBD (cannabidiol) is a naturally-occurring cannabinoid of the terpenophenolic class. It is the primary non-intoxicating compound in cannabis, distinct from Δ⁹-THC. It modulates serotonin receptors and the body's own cannabinoid system without directly activating the brain's main cannabinoid receptor, producing symptom relief without intoxication.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Roger Adams first isolated CBD from cannabis in 1940; Raphael Mechoulam determined its full structure in 1963. Dramatic pediatric epilepsy cases in the early 2010s drove clinical investment, culminating in FDA approval of Epidiolex in 2018.[1] CBD is now one of the most widely used supplements globally, with active research into anxiety, psychosis, and other conditions.[2]
Subjective effects include anxiety suppression, muscle relaxation, mild sedation, and pain suppression. The experience is defined by what it removes — tension, discomfort, and anxiety quiet without euphoria, perceptual change, or altered consciousness. Drowsiness, diarrhea, and appetite changes are common at higher doses.
CBD produces no physical dependence and no withdrawal; liver toxicity is the principal medical concern, particularly at high doses or when combined with valproate.[3] The more common everyday danger is drug interaction: CBD inhibits the liver enzyme that metabolizes many common medications, raising their blood levels. Decades of clinical epilepsy data provide a strong safety foundation, though effects in non-epilepsy populations remain incompletely understood.
History[edit]
Discovery
Roger Adams first isolated cannabidiol from cannabis in 1940; Alexander Todd made the same isolation independently around the same time.[4][5][6] Raphael Mechoulam determined its precise structure in 1963 — a year before he identified THC as the primary intoxicating constituent of cannabis.[4][5] That finding established CBD as pharmacologically distinct and set the direction for all subsequent research.
Clinical breakthrough
CBD attracted little clinical attention for decades, with early studies suggesting anticonvulsant and anxiety-reducing properties but not advancing further.[5][7] A 2013 CNN documentary about a child with Dravet syndrome responding dramatically to a high-CBD cannabis extract called "Charlotte's Web" drove pharmaceutical investment. A 2017 landmark trial showed CBD reduced convulsive seizures by 38.9% compared to 13.3% for placebo, leading to FDA approval of Epidiolex in 2018.[1][8]
Regulatory milestones
The 2018 US Farm Bill legalized hemp-derived CBD federally, while the FDA simultaneously prohibited its use in foods and dietary supplements. Australia approved Epidyolex in 2020, the FDA expanded coverage to tuberous sclerosis complex in 2021, and by 2026 European food safety authorities had established a provisional safe dose for supplement use — substantially below clinical dosing ranges.[3]
The name cannabidiol derives from Cannabis (the plant genus) and the chemical suffix -diol, indicating its two hydroxyl groups. In consumer culture, "CBD" has become a near-universal abbreviation, appearing on products from tinctures to pet treats. The compound's non-intoxicating reputation drove an explosion of unregulated consumer products following the 2018 Farm Bill, creating a market where quality varies enormously and therapeutic claims routinely outpace evidence.
Chemistry[edit]
Structural class
Cannabidiol belongs to the terpenophenolic phytocannabinoids — naturally occurring compounds found in cannabis. Unlike Δ⁹-THC, CBD lacks the fused oxygen bridge that allows direct binding at the brain's primary cannabinoid receptor. The molecular formula is C₂₁H₃₀O₂ (molecular weight 314.5 g/mol), and this single structural difference is why CBD produces no euphoria or intoxication.
Key properties
The naturally occurring form is (-)-CBD; its mirror image has a substantially different pharmacological profile.[9] All approved pharmaceutical products use the natural form. CBD is highly fat-soluble and nearly impossible to dissolve in water,[10][11] which is why it requires oil-based formulations and why taking it with a fatty meal substantially increases absorption.
Pharmacology[edit]
Mechanism of action
CBD acts on at least six molecular targets without directly activating the brain's primary cannabinoid receptor.[9][12] Rather than binding CB1 directly, it modulates it from the outside — subtly reducing the receptor's sensitivity to other cannabinoids.[13][14] This is why CBD produces no euphoria or intoxication.
CBD also partially activates serotonin receptors — the same target as the anxiolytic buspirone — producing anxiety relief and anti-nausea effects.[15][12][16] It slows the enzyme that breaks down anandamide, the brain's own cannabinoid, raising its levels.[9][17] In a clinical schizophrenia trial, anandamide elevation correlated directly with symptom improvement.[18]
Pharmacokinetics
Oral bioavailability is low and highly variable (6–20%), because the liver breaks down much of each dose before it reaches the bloodstream.[3] A high-fat meal dramatically increases absorption — pharmaceutical CBD is taken with food. Peak blood levels arrive 1.5–5 hours after dosing; subjective effects last roughly 1.5–4 hours, though the compound lingers in the body much longer — the half-life extends to 18–32 hours with repeated dosing.
Neuroscience[edit]
Where it acts
CBD modulates brain function through endocannabinoid, serotonin, and other pathways — not through direct cannabinoid receptor activation like THC. By slowing the breakdown of anandamide, CBD strengthens the brain's own cannabinoid signaling.[9] In the amygdala, this reduces fear responses; in the hippocampus, it shapes memory and extinction learning.
Why it matters
In a clinical schizophrenia trial, CBD-induced anandamide elevation correlated with symptom improvement,[18] confirming endocannabinoid augmentation as a real mechanism for its neuropsychiatric effects. CBD's partial serotonin receptor activation engages the same feedback systems targeted by buspirone-class anxiolytics,[12] and also accounts for its anti-nausea effects.[19][20]
CBD's efficacy in treatment-resistant epilepsy illustrates the advantage of hitting multiple brain systems simultaneously.[21] Seizure suppression comes from reduced neuronal excitability and elevated adenosine activating inhibitory pathways.[22][23] Anti-inflammatory effects in brain immune cells may add neuroprotection in epileptic networks.[24]
The optimal dose for non-epilepsy applications remains unestablished. Whether the inverted U-shaped dose-response curve seen in animal anxiety models applies to human psychiatric outcomes is unresolved. How much CBD actually reaches brain serotonin receptors at clinical doses — given its low bioavailability and heavy protein binding — has not been directly measured in humans.
Subjective Effects[edit]
CBD's experience is defined by removal. Anxiety quiets, muscles loosen, and tension fades — without euphoria, perceptual shift, or any sense of intoxication. It reads less like being affected and more like a layer of discomfort being lifted. Responses vary considerably between individuals, even at the same dose.
Compared to Δ⁹-THC, CBD occupies an entirely separate experiential category. THC produces euphoria, time alteration, and appetite stimulation; CBD produces anxiolysis and physical calming without any of those qualities. It sits closer in character to buspirone or a mild adaptogen than to any traditional cannabinoid.
Effect Grid
Moderate anxiety suppression and mild sedation characterize the common dose range. Muscle relaxation becomes clearly noticeable. This is the range most commonly used in wellness and supplement contexts for general anxiolysis and stress reduction. CBD remains non-intoxicating — no euphoria, no altered perception, no cognitive impairment.
Mild drowsiness may emerge, particularly when taken with food (which increases bioavailability) or in the evening. Faint pain suppression may be perceptible in individuals with mild chronic pain. No significant gastrointestinal effects at this range for most users.
Subjective effects last approximately 1.5–4 hours. The anxiolytic dose-response may follow an inverted U-curve — higher doses are not necessarily more effective for anxiety reduction.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Constipation · Dizziness · Physical fatigue · Appetite suppression · Dry mouth · Headache · Nausea · Wakefulness · Vomiting
Dry mouth · Headache · Nausea · Wakefulness · Vomiting
Timeline
Initial subtle anxiolysis begins — a faint softening of baseline tension that may be difficult to distinguish from placebo at lower doses. No perceptual or cognitive changes.
Anxiety reduction deepens and mild relaxation emerges. Muscle tension begins to ease. Effects remain subtle and non-intoxicating.
Maximum anxiolysis and sedation. Muscle relaxation is most pronounced. Mild drowsiness may be present at common doses and above.
Effects gradually diminish. Residual calm and muscle relaxation persist. Sedation tapers but drowsiness may linger, particularly at higher doses.
Mild residual relaxation and improved sleep quality in evening doses. Active metabolite 7-OH-CBD contributes to extended pharmacological activity beyond the subjective window.
⚠ Avoid driving or operating machinery if sedation persists, particularly at doses above 30 mg.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- None
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
CBD has a wide safety margin. No human lethal dose has been established, and doses up to 1,500 mg/day have been administered in studies without acute toxicity.[26]
Liver toxicity
Liver toxicity is the principal dose-limiting risk for CBD. Liver function monitoring is required during treatment with pharmaceutical CBD (Epidiolex), particularly when co-administered with valproate.
Liver toxicity is the main dose-limiting concern.[3] The lowest dose at which liver effects have been observed in humans is approximately 300 mg/day; at 60 mg/day, no liver effects were seen in healthy athletes.[27] Elevated liver enzymes were observed in epilepsy trials, particularly alongside valproate.[28]
Liver function tests should be obtained at baseline and at 1, 3, and 6 months during treatment.[29][30]
Gastrointestinal effects
Diarrhea (affecting about 12% of people in expanded access programs), nausea, and appetite changes are common at clinical doses.[29][26]
Reproductive and developmental toxicity
Safety cannot be established for pregnant or breastfeeding women, people under 25 outside approved indications, or anyone on concurrent medications.[3] CBD crosses the placenta, and animal studies demonstrate developmental effects. No controlled human reproductive data exist.
Endocrine and cardiovascular effects
Animal studies show altered thyroid and adrenal hormone levels;[3] human endocrine effects at clinical doses have not been systematically studied. CBD does not raise heart rate like THC, and no significant cardiovascular effects are documented at therapeutic doses.[31]
Psychological risks
CBD does not produce psychological distress, psychotic symptoms, or cognitive impairment at any studied dose. It has demonstrated antipsychotic effects in a clinical schizophrenia trial.[32]
Drowsiness is the most common neuropsychiatric adverse effect, affecting about 22% of epilepsy patients.[29] This warrants caution around driving and operating machinery. No persistent perceptual changes or psychiatric destabilization have been attributed to CBD.
Tolerance and dependence
No tolerance develops to CBD's anticonvulsant effects — long-term trials show sustained seizure reduction without dose escalation over years.[21][33][34] This contrasts with THC, which produces tolerance through downregulation.
No physical or psychological dependence has been documented at any dose.[35] No withdrawal has been described after stopping; in combination products with THC, any dependence signals are attributed to the THC component.[36] The DEA's Schedule V placement of Epidiolex reflects regulatory consensus that CBD has essentially no abuse potential.
Drug interactions
CBD's most important drug interactions come from inhibiting CYP2C19, a liver enzyme that metabolizes many common medications. When CBD slows this enzyme, affected medications build up in the blood, amplifying their effects.
The most clinically significant interaction is with clobazam — CBD elevates its active metabolite's levels, often requiring dose reduction.[37][38] CBD similarly increases exposure to SSRIs such as citalopram.[39] Chronic CBD use can convert CYP2C19 enzyme activity from normal to functionally poor, affecting drug processing beyond those taken alongside CBD.[25]
Combining CBD with valproate elevates liver enzyme levels through a mechanism that is not fully understood.[37] Strong CYP3A4 inducers — including rifampicin, phenytoin, and carbamazepine — can reduce CBD blood levels, potentially making it ineffective.[37] Additive sedation occurs with benzodiazepines, opioids, and other central nervous system depressants.
Contraindications
Absolute contraindications:
- Pregnancy and lactation. CBD crosses the placenta; animal studies demonstrate developmental toxicity. EFSA concludes safety cannot be established.[3]
- Severe liver disease. Pre-existing liver impairment increases the risk of CBD-induced liver toxicity given the compound's hepatic metabolism.
Relative contraindications:
- Concurrent valproate therapy without liver function monitoring.[30]
- Concurrent CYP2C19 substrate medications without dose adjustment, including clobazam, citalopram, and diazepam.[37][39]
- Age under 25 for non-medical use. EFSA concludes safety has not been established for this population outside approved indications.[3]
- Concurrent strong CYP3A4 inducers. Rifampicin, phenytoin, and carbamazepine reduce CBD blood levels, potentially rendering it ineffective.[37]
Harm Reduction[edit]
Forms & Identification
CBD products span an enormous quality range, from pharmaceutical-grade Epidiolex (standardized at 100 mg/mL) to unregulated tinctures, capsules, edibles, topicals, and vape liquids. Independent testing repeatedly finds consumer products containing far less CBD than labeled, as well as unlabeled THC and other contaminants. A third-party certificate of analysis from an accredited laboratory is essential for any consumer-grade product.
Isolate, broad-spectrum, and full-spectrum formulations differ in their content of other cannabinoids. Full-spectrum products contain trace THC (up to 0.3%), which may be sufficient to trigger a positive drug test.
Guidelines
- Start with a low dose (5–10 mg) and increase gradually over days, not hours
- Take oral CBD with food — a meal containing fat substantially increases absorption
- Use products with a current third-party certificate of analysis from an accredited laboratory
- If taking prescription medications, consult a pharmacist or physician about potential interactions before starting CBD — particularly if taking clobazam, valproate, SSRIs, or benzodiazepines
- Monitor for excessive drowsiness, especially when combined with other sedating substances
- If using CBD at clinical doses (above 100 mg/day), request baseline liver function tests and periodic monitoring
Set & Setting
CBD does not alter consciousness, so set and setting matter far less than with psychoactive substances. The main practical consideration is timing: higher doses cause drowsiness, making evening use preferable for those sensitive to sedation. Because bioavailability varies substantially between individuals and formulations, start with the lowest available dose and assess effects before increasing.
Aftercare & integration. CBD does not produce altered states requiring formal integration. If sedation was pronounced, allow adequate sleep before driving or operating machinery. Those using CBD for anxiety or sleep should track the response over at least a week before adjusting doses — effects may shift with accumulation given the compound's long half-life (18–32 hours with repeated dosing).
If discontinuing after sustained high-dose use, tapering is not pharmacologically necessary — no withdrawal has been documented — but gradual reduction helps distinguish returning symptoms from discontinuation effects.
Recovery & Support
CBD does not produce dependence or compulsive use patterns. Individuals using CBD as a substitute for evidence-based treatments for anxiety, depression, or chronic pain should periodically reassess whether it is providing meaningful benefit. If CBD is being used to manage symptoms of an underlying condition, professional evaluation ensures effective treatments are not delayed or replaced. For those using CBD alongside recovery from other substance dependencies, disclosure to treatment providers ensures accurate medication interaction assessment.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
CBD alone has not produced life-threatening toxicity in any documented case. However, contaminated or mislabeled products — or interactions with other substances — can create emergencies.
Recognizing a problem:
- Severe drowsiness or unresponsiveness beyond normal sedation
- Signs of allergic reaction (difficulty breathing, swelling, hives)
- Yellowing of skin or eyes, dark urine, or persistent nausea (signs of liver injury — seek medical attention)
If someone is unresponsive:
- 1. Call emergency services
- 2. Place the person on their side (recovery position)
- 3. Do not induce vomiting
- 4. Stay with the person until help arrives
What to tell the dispatcher: the substance taken (CBD product, with brand if known), the amount, when it was taken, any other substances or medications involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during drug-related emergencies.
Legal Status[edit]
CBD's legal status depends on the source plant, intended use, and jurisdiction — and continues to change.
Legal status changes frequently. This information reflects the position as of early 2026 and is not legal advice.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (hemp-derived) | Legal (2018 Farm Bill) | Hemp-derived CBD (from cannabis with less than 0.3% THC) is federally legal. FDA prohibits addition to foods, beverages, or dietary supplements due to CBD's approved drug status[40] |
| United States (Epidiolex) | Schedule V (DEA, 2018); rescheduled to Schedule III (April 2026) | Prescription required; approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex |
| United Kingdom | Legal without prescription | Novel food regulations apply; products exceeding 1 mg THC per package are restricted. Epidiolex available on NHS prescription for severe pediatric epilepsy |
| European Union | Generally permitted; novel food status | ECJ ruled CBD is not a narcotic (2020). Novel food authorization pending for food supplements as of 2026[3] |
| Canada | Regulated under Cannabis Act (2018) | Requires licensed producers. CBD products fall under cannabis regulation; hemp exemptions apply under threshold conditionscitation needed |
| Australia | Schedule 4 (prescription); Schedule 3 (OTC, theoretical) | TGA down-scheduled low-dose CBD to Schedule 3 (OTC) in December 2020 but no OTC products registered as of 2026. Epidyolex TGA-approved September 2020; PBS-listed for Dravet syndrome from May 2021 |
references
- [1] ^abDevinsky O, Cross JH, Laux L, et al. (2017) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome — New England Journal of Medicine doi:10.1056/nejmoa1611618
- [2] ^O'Sullivan SE, Jensen SS, Nikolajsen GN, et al. (2023) The therapeutic potential of purified cannabidiol — Journal of Cannabis Research doi:10.1186/s42238-023-00186-9
- [3]
- [4] ^abPertwee RG (2006) Cannabinoid pharmacology: the first 66 years — British Journal of Pharmacology PMID:16402100
- [5] ^abcZuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action — Revista Brasileira de Psiquiatria PMID:18833429
- [6] ^Hanus LO, Meyer S, Munoz E, Taglialatela-Scafati O, Appendino G (2016) Phytocannabinoids: a unified critical inventory — Natural Product Reports doi:10.1039/c6np00074f